CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SPRYD7 (ImmuneEditome ID:57213)

1. Gene summary of enriched editing regions for SPRYD7

check button Gene summary
Gene informationGene symbol

SPRYD7

Gene ID

57213

GeneSynonymsC13orf1|CLLD6
GeneCytomap

13q14.2

GeneTypeprotein-coding
GeneDescriptionSPRY domain-containing protein 7|CLL deletion region gene 6 protein|chronic lymphocytic leukemia deletion region gene 6 protein|epididymis secretory sperm binding protein
GeneModificationdate20230329
UniprotIDQ5W111
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr13:49913107-49913915:-ENST00000613924.1ENSG00000123178.13SPRYD7splicingMIR,MER5A,AluSx1,AluYchr13:49913107-49913915:-.alignment
chr13:49917165-49918694:-ENST00000361840.6ENSG00000123178.13SPRYD7intronicAluJb,AluSz,AluYchr13:49917165-49918694:-.alignment
chr13:49917165-49918694:-ENST00000378195.5ENSG00000123178.13SPRYD7intronicAluJb,AluSz,AluYchr13:49917165-49918694:-.alignment
chr13:49917165-49918694:-ENST00000613924.1ENSG00000123178.13SPRYD7intronicAluJb,AluSz,AluYchr13:49917165-49918694:-.alignment


Top

2. Tumor-specific enriched editing regions for SPRYD7


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr13:49913107-49913915:-BRCAEER2.9936e-02image
ENSG00000123178.13,SPRYD7BRCAEAG2.6921e-02image
chr13:49913107-49913915:-COADEER2.2114e-02image
ENSG00000123178.13,SPRYD7COADEAG1.0976e-02image
chr13:49913107-49913915:-HNSCEER5.3131e-05image
ENSG00000123178.13,SPRYD7HNSCEAG5.3403e-05image
chr13:49913107-49913915:-LUADEER5.2207e-06image
ENSG00000123178.13,SPRYD7LUADEAG5.7523e-06image
chr13:49913107-49913915:-LUSCEER9.0000e-04image
ENSG00000123178.13,SPRYD7LUSCEAG1.1323e-03image
chr13:49913107-49913915:-STADEER4.0866e-03image
ENSG00000123178.13,SPRYD7STADEAG5.4018e-03image
chr13:49913107-49913915:-THCAEER1.4108e-03image
ENSG00000123178.13,SPRYD7THCAEAG1.4157e-03image
chr13:49913107-49913915:-UCECEER1.4625e-02image
ENSG00000123178.13,SPRYD7UCECEAG1.2898e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000123178.13,SPRYD7KIRCPathEAG4.8432e-053.2842e-050.1833image
chr13:49913107-49913915:-KIRCPathEER3.4813e-052.9414e-050.1844image
ENSG00000123178.13,SPRYD7MESOPathEAG4.5153e-028.6477e-030.3477image
chr13:49913107-49913915:-MESOPathEER4.5153e-028.6477e-030.3477image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for SPRYD7


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr13:49913107-49913915:-COADEERENSG00000101417,PXMP4-0.41628.1155e-085.3069e-11-0.4004imageNFUS;PRPF8;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_BILE_ACID_METABOLISM
chr13:49913107-49913915:-COADEERENSG00000123178,SPRYD7-0.40281.6725e-074.6468e-12-0.4200imageNFUS;LIN28;PRPF8;U2AF2NAEosinophilsGSVA_HALLMARK_APICAL_SURFACE
chr13:49913107-49913915:-COADEERENSG00000120875,DUSP40.39742.3823e-074.6501e-120.4200imageNFUS;U2AF2NAMacrophages_M0GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr13:49913107-49913915:-COADEERENSG00000197712,FAM114A10.39563.4187e-071.9446e-120.4267imageNFUS;LIN28;PRPF8;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr13:49913107-49913915:-COADEERENSG00000157613,CREB3L10.36774.2354e-066.8353e-140.4512imageNFUS;LIN28;PRPF8;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr13:49913107-49913915:-COADEERENSG00000181826,RELL10.34232.6414e-051.4025e-110.4112imageNFUS;LIN28;PRPF8;U2AF2NANeutrophilsGSVA_HALLMARK_PEROXISOME
chr13:49913107-49913915:-COADEERENSG00000106546,AHR0.31631.2444e-049.9706e-120.4140imageNFUS;LIN28;PRPF8;U2AF2AHRNeutrophilsGSVA_HALLMARK_PEROXISOME
chr13:49913107-49913915:-COADEERENSG00000141664,ZCCHC20.31241.3586e-042.1947e-120.4258imageNFUS;LIN28;PRPF8;U2AF2NANeutrophilsGSVA_HALLMARK_PEROXISOME
chr13:49913107-49913915:-COADEERENSG00000166579,NDEL10.31621.4543e-048.6949e-130.4328imageNFUS;LIN28;PRPF8;U2AF2NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
chr13:49913107-49913915:-COADEERENSG00000147459,DOCK50.28714.0216e-044.2475e-110.4022imageNFUS;LIN28;PRPF8;U2AF2DOCK5EosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for SPRYD7


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000007392.12chr16208077:208188:208600:2086570.19274.8021e-021.0035e-160.5674imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RTCB;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZC3H7B;ZFP36;ZNF184NAMast_cells_activatedGSVA_HALLMARK_PEROXISOME
chr13:49913107-49913915:-
COADEERIRENSG00000138002.10chr227445013:27445449:27445928:274459880.27664.7715e-033.8691e-160.4856imageNFUS;LIN28;PRPF8;U2AF2IFT172EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000134909.14chr11128965059:128973432:128974123:1289750020.23323.4335e-022.3122e-180.5254imageNACIN1;ADAR;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM47;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;ZC3H7B;ZFP36NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000171604.7chr5139680363:139681447:139682862:1396831110.25491.6207e-026.6289e-200.5376imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1NANeutrophilsGSVA_HALLMARK_PEROXISOME
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000161960.10chr177573843:7574308:7574547:75746780.23474.2157e-024.7681e-150.4686imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RTCB;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_ADIPOGENESIS
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000186340.10chr6169246064:169246281:169248416:1692486800.23743.9644e-032.7738e-250.6750imageNADAR;CSTF2T;DGCR8;DKC1;ELAVL1;ELAVL3;FAM120A;FUS;HNRNPL;IGF2BP2;MBNL2;MSI1;NOP56;RBFOX2;RBM47;SND1;TAF15;TARDBP;TROVE2;UPF1THBS2Mast_cells_activatedGSVA_HALLMARK_P53_PATHWAY
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000244754.4chr1332516893:32518003:32521372:325214490.23413.5034e-022.5982e-210.5526imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RTCB;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZFP36;ZNF184NAMast_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000221978.7chr11390765:1392803:1393395:13934390.24312.8197e-023.8969e-330.6638imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000058673.11chr1203795653:203796496:203801574:2038016280.31411.6148e-041.4710e-190.5665imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RTCB;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZFP36;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR
ENSG00000123178.13,SPRYD7
COADEAGIRENSG00000138002.10chr227445013:27445449:27445928:274459880.27107.5335e-033.8711e-160.4856imageNACIN1;ADAR;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184IFT172EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

5. Enriched editing regions and immune infiltration for SPRYD7


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr13:49913107-49913915:-BLCAEERNK_cells_resting3.0519e-030.1771image
ENSG00000123178.13,SPRYD7BLCAEAGNK_cells_resting3.0711e-030.1770image
chr13:49913107-49913915:-CESCEERDendritic_cells_resting4.9172e-02-0.1304image
ENSG00000123178.13,SPRYD7CESCEAGDendritic_cells_resting4.9172e-02-0.1304image
chr13:49913107-49913915:-COADEERNeutrophils2.1547e-030.1936image
ENSG00000123178.13,SPRYD7COADEAGDendritic_cells_activated1.3131e-040.2395image
chr13:49913107-49913915:-ESCAEERDendritic_cells_resting1.1596e-02-0.2056image
ENSG00000123178.13,SPRYD7ESCAEAGDendritic_cells_resting9.4831e-03-0.2112image
chr13:49913107-49913915:-GBMEERMacrophages_M05.0597e-03-0.2227image
ENSG00000123178.13,SPRYD7GBMEAGMacrophages_M05.0711e-03-0.2226image
chr13:49913107-49913915:-HNSCEERNeutrophils7.1026e-030.1403image
ENSG00000123178.13,SPRYD7HNSCEAGNeutrophils7.0563e-030.1404image
chr13:49913107-49913915:-KICHEERMacrophages_M03.3073e-030.3763image
ENSG00000123178.13,SPRYD7KICHEAGMacrophages_M03.3073e-030.3763image
chr13:49913107-49913915:-KIRCEERT_cells_gamma_delta1.8612e-030.1612image
ENSG00000123178.13,SPRYD7KIRCEAGT_cells_gamma_delta1.6196e-030.1633image
chr13:49913107-49913915:-KIRPEERPlasma_cells9.0513e-040.2027image
ENSG00000123178.13,SPRYD7KIRPEAGPlasma_cells9.0647e-040.2027image
chr13:49913107-49913915:-LGGEERT_cells_CD4_naive2.9737e-04-0.1588image
ENSG00000123178.13,SPRYD7LGGEAGT_cells_CD4_naive2.9737e-04-0.1588image
chr13:49913107-49913915:-LUADEERNK_cells_resting1.7896e-020.1344image
ENSG00000123178.13,SPRYD7LUADEAGNK_cells_resting1.6483e-020.1361image
chr13:49913107-49913915:-LUSCEERT_cells_CD81.1366e-050.2294image
ENSG00000123178.13,SPRYD7LUSCEAGT_cells_CD87.1729e-060.2344image
chr13:49913107-49913915:-MESOEERMonocytes4.9011e-02-0.2667image
ENSG00000123178.13,SPRYD7MESOEAGMonocytes4.9011e-02-0.2667image
chr13:49913107-49913915:-PAADEERT_cells_CD4_memory_resting4.4129e-02-0.1735image
ENSG00000123178.13,SPRYD7PAADEAGT_cells_CD4_memory_resting4.2956e-02-0.1745image
chr13:49913107-49913915:-PCPGEERT_cells_regulatory_(Tregs)1.5341e-020.1795image
ENSG00000123178.13,SPRYD7PCPGEAGT_cells_regulatory_(Tregs)1.6542e-020.1775image
chr13:49913107-49913915:-PRADEERT_cells_regulatory_(Tregs)1.6042e-020.1155image
ENSG00000123178.13,SPRYD7PRADEAGT_cells_regulatory_(Tregs)1.6636e-020.1148image
chr13:49913107-49913915:-READEERDendritic_cells_resting3.7422e-02-0.2222image
ENSG00000123178.13,SPRYD7READEAGDendritic_cells_resting4.2118e-02-0.2159image
chr13:49913107-49913915:-SARCEERDendritic_cells_resting4.5373e-020.1830image
ENSG00000123178.13,SPRYD7SARCEAGDendritic_cells_resting4.5373e-020.1830image
chr13:49913107-49913915:-SKCMEERT_cells_CD81.5710e-050.2136image
ENSG00000123178.13,SPRYD7SKCMEAGT_cells_CD81.6090e-050.2133image
chr13:49913107-49913915:-STADEERT_cells_CD4_memory_activated1.1019e-030.1791image
chr13:49917165-49918694:-STADEEREosinophils2.7371e-02-0.2601image
ENSG00000123178.13,SPRYD7STADEAGT_cells_CD4_memory_activated5.1097e-040.1903image
chr13:49913107-49913915:-TGCTEERMast_cells_activated5.8884e-050.4215image
ENSG00000123178.13,SPRYD7TGCTEAGMast_cells_activated5.6347e-050.4225image
chr13:49913107-49913915:-THCAEERMacrophages_M23.7935e-03-0.1307image
ENSG00000123178.13,SPRYD7THCAEAGMacrophages_M23.7873e-03-0.1307image
chr13:49913107-49913915:-THYMEERDendritic_cells_activated5.2360e-03-0.3132image
ENSG00000123178.13,SPRYD7THYMEAGDendritic_cells_activated5.5572e-03-0.3112image
chr13:49913107-49913915:-UCECEERMacrophages_M01.9772e-020.2171image
chr13:49913107-49913915:-UCSEERB_cells_naive2.6606e-020.3694image
ENSG00000123178.13,SPRYD7UCSEAGB_cells_naive2.6606e-020.3694image
chr13:49913107-49913915:-UVMEERMonocytes2.4938e-030.4184image
ENSG00000123178.13,SPRYD7UVMEAGMonocytes2.4938e-030.4184image


Top

6. Enriched editing regions and immune gene sets for SPRYD7


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr13:49913107-49913915:-BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7751e-020.1421image
ENSG00000123178.13,SPRYD7BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7963e-020.1418image
chr13:49913107-49913915:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1096e-030.1108image
ENSG00000123178.13,SPRYD7BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4787e-030.1080image
chr13:49913107-49913915:-CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.4987e-040.2271image
ENSG00000123178.13,SPRYD7CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.4987e-040.2271image
ENSG00000123178.13,SPRYD7COADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.0666e-06-0.3028image
chr13:49913107-49913915:-COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.2890e-05-0.2725image
chr13:49913107-49913915:-ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.0320e-050.3403image
ENSG00000123178.13,SPRYD7ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.4092e-060.3649image
chr13:49913107-49913915:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.0077e-070.3884image
ENSG00000123178.13,SPRYD7GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.0788e-070.3882image
chr13:49913107-49913915:-HNSCGSVA_HALLMARK_P53_PATHWAYEER4.1965e-030.1491image
ENSG00000123178.13,SPRYD7HNSCGSVA_HALLMARK_P53_PATHWAYEAG4.1828e-030.1492image
ENSG00000123178.13,SPRYD7KIRCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.0596e-050.2149image
chr13:49913107-49913915:-KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.6549e-050.2100image
chr13:49913107-49913915:-KIRPGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.5462e-030.1847image
ENSG00000123178.13,SPRYD7KIRPGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.5572e-030.1846image
ENSG00000123178.13,SPRYD7LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.5598e-090.2564image
chr13:49913107-49913915:-LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.5598e-090.2564image
ENSG00000123178.13,SPRYD7LUSCGSVA_HALLMARK_GLYCOLYSISEAG1.5057e-03-0.1669image
chr13:49913107-49913915:-LUSCGSVA_HALLMARK_GLYCOLYSISEER1.4471e-03-0.1675image
chr13:49913107-49913915:-MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.9898e-02-0.2657image
ENSG00000123178.13,SPRYD7MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.9898e-02-0.2657image
chr13:49913107-49913915:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.5148e-030.1800image
ENSG00000123178.13,SPRYD7OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.9001e-030.1836image
ENSG00000123178.13,SPRYD7PAADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG6.1216e-030.2348image
chr13:49913107-49913915:-PAADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER6.2789e-030.2341image
chr13:49913107-49913915:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.8594e-050.2907image
ENSG00000123178.13,SPRYD7PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.5933e-050.2914image
chr13:49913107-49913915:-PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.4626e-03-0.1400image
ENSG00000123178.13,SPRYD7PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.9885e-03-0.1420image
chr13:49913107-49913915:-READGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER8.6451e-03-0.2783image
ENSG00000123178.13,SPRYD7READGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.1420e-03-0.2788image
ENSG00000123178.13,SPRYD7SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.8856e-020.2141image
chr13:49913107-49913915:-SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8856e-020.2141image
chr13:49913107-49913915:-SKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.8918e-050.2116image
ENSG00000123178.13,SPRYD7SKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.2598e-050.2096image
chr13:49913107-49913915:-STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER7.5782e-030.1470image
ENSG00000123178.13,SPRYD7STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.6110e-030.1652image
chr13:49917165-49918694:-STADGSVA_HALLMARK_HEME_METABOLISMEER1.4466e-030.3685image
chr13:49913107-49913915:-THCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER4.0188e-030.1299image
ENSG00000123178.13,SPRYD7THCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG3.9696e-030.1300image
chr13:49913107-49913915:-THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.6560e-020.2706image
ENSG00000123178.13,SPRYD7THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.5566e-020.2731image
chr13:49913107-49913915:-UCECGSVA_HALLMARK_APICAL_JUNCTIONEER7.4610e-030.2483image
ENSG00000123178.13,SPRYD7UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEAG5.4069e-030.2556image
chr13:49913107-49913915:-UCSGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.5826e-03-0.4729image
ENSG00000123178.13,SPRYD7UCSGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.5826e-03-0.4729image
chr13:49913107-49913915:-UVMGSVA_HALLMARK_KRAS_SIGNALING_UPEER2.5535e-02-0.3157image
ENSG00000123178.13,SPRYD7UVMGSVA_HALLMARK_KRAS_SIGNALING_UPEAG2.5535e-02-0.3157image


Top

7. Enriched editing regions and drugs for SPRYD7


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000123178.13,SPRYD7ACCGSK269962AEAG3.1940e-02-0.2480image
chr13:49913107-49913915:-ACCGSK269962AEER3.1940e-02-0.2480image
chr13:49913107-49913915:-BLCAGefitinibEER2.8407e-03-0.1784image
ENSG00000123178.13,SPRYD7BLCAGefitinibEAG2.8526e-03-0.1783image
chr13:49913107-49913915:-CESCAZD.2281EER5.4109e-05-0.2641image
ENSG00000123178.13,SPRYD7CESCAZD.2281EAG5.4109e-05-0.2641image
ENSG00000123178.13,SPRYD7CHOLBX.795EAG1.7706e-02-0.4166image
chr13:49913107-49913915:-CHOLBX.795EER1.7958e-02-0.4157image
ENSG00000123178.13,SPRYD7COADBMS.708163EAG4.1154e-06-0.2866image
chr13:49913107-49913915:-COADAZD8055EER2.5086e-04-0.2301image
chr13:49913107-49913915:-ESCAFH535EER3.2177e-040.2898image
ENSG00000123178.13,SPRYD7ESCAFH535EAG3.0474e-030.2404image
chr13:49913107-49913915:-GBMBIBW2992EER1.3146e-03-0.2542image
ENSG00000123178.13,SPRYD7GBMBIBW2992EAG1.3249e-03-0.2540image
ENSG00000123178.13,SPRYD7HNSCCMKEAG2.2523e-04-0.1914image
chr13:49913107-49913915:-HNSCCMKEER2.1432e-04-0.1921image
ENSG00000123178.13,SPRYD7KICHA.443654EAG2.4178e-02-0.2933image
chr13:49913107-49913915:-KICHA.443654EER2.4178e-02-0.2933image
ENSG00000123178.13,SPRYD7KIRCBMS.536924EAG3.7849e-07-0.2607image
chr13:49913107-49913915:-KIRCBMS.536924EER3.6957e-07-0.2610image
chr13:49913107-49913915:-KIRPAZD7762EER6.0528e-03-0.1682image
ENSG00000123178.13,SPRYD7KIRPAZD7762EAG6.1625e-03-0.1679image
ENSG00000123178.13,SPRYD7LGGCMKEAG4.6093e-15-0.3361image
chr13:49913107-49913915:-LGGCMKEER4.6093e-15-0.3361image
ENSG00000123178.13,SPRYD7LIHCGNF.2EAG1.3197e-05-0.2622image
chr13:49913107-49913915:-LIHCGNF.2EER1.3312e-05-0.2621image
ENSG00000123178.13,SPRYD7LUADAICAREAG4.0830e-03-0.1627image
chr13:49913107-49913915:-LUADAICAREER3.8680e-03-0.1636image
ENSG00000123178.13,SPRYD7LUSCBAY.61.3606EAG8.6198e-04-0.1751image
chr13:49913107-49913915:-LUSCBAY.61.3606EER8.2570e-04-0.1757image
chr13:49913107-49913915:-MESOAxitinibEER1.6986e-02-0.3207image
ENSG00000123178.13,SPRYD7MESOAxitinibEAG1.6986e-02-0.3207image
chr13:49913107-49913915:-OVEmbelinEER3.3855e-030.1808image
ENSG00000123178.13,SPRYD7OVEmbelinEAG2.9334e-030.1834image
chr13:49913107-49913915:-PAADGemcitabineEER3.9670e-03-0.2464image
ENSG00000123178.13,SPRYD7PAADGemcitabineEAG3.8799e-03-0.2470image
chr13:49913107-49913915:-PCPGBMS.536924EER8.2915e-04-0.2463image
ENSG00000123178.13,SPRYD7PCPGBMS.536924EAG8.1343e-04-0.2467image
chr13:49913107-49913915:-PRADAZD.2281EER6.8892e-05-0.1903image
ENSG00000123178.13,SPRYD7PRADAZD.2281EAG1.0608e-04-0.1852image
ENSG00000123178.13,SPRYD7READBortezomibEAG1.8126e-040.3868image
chr13:49913107-49913915:-READBortezomibEER1.8700e-040.3881image
ENSG00000123178.13,SPRYD7SARCBortezomibEAG4.3455e-03-0.2586image
chr13:49913107-49913915:-SARCBortezomibEER4.3455e-03-0.2586image
chr13:49913107-49913915:-SKCMCGP.082996EER5.2740e-05-0.2002image
ENSG00000123178.13,SPRYD7SKCMCGP.082996EAG5.5242e-05-0.1997image
ENSG00000123178.13,SPRYD7STADCamptothecinEAG4.3454e-03-0.1566image
chr13:49913107-49913915:-STADCisplatinEER3.3993e-03-0.1610image
chr13:49913107-49913915:-TGCTCyclopamineEER3.6810e-02-0.2269image
ENSG00000123178.13,SPRYD7TGCTCyclopamineEAG3.3119e-02-0.2314image
ENSG00000123178.13,SPRYD7THCAKU.55933EAG5.3697e-05-0.1816image
chr13:49913107-49913915:-THCAKU.55933EER5.4125e-05-0.1815image
ENSG00000123178.13,SPRYD7THYMCGP.60474EAG1.7096e-02-0.2693image
chr13:49913107-49913915:-THYMCGP.60474EER1.7823e-02-0.2677image
chr13:49913107-49913915:-UCECJNJ.26854165EER2.7075e-03-0.2772image
ENSG00000123178.13,SPRYD7UCECJNJ.26854165EAG2.0020e-03-0.2828image
chr13:49913107-49913915:-UVMABT.888EER2.9788e-020.3076image
ENSG00000123178.13,SPRYD7UVMABT.888EAG2.9788e-020.3076image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType